CDKN2D Antibody (monoclonal) (M08)
Mouse monoclonal antibody raised against a full-length recombinant CDKN2D.
|Application ||WB, IP, E|
|Calculated MW||17700 Da|
|Other Names||Cyclin-dependent kinase 4 inhibitor D, p19-INK4d, CDKN2D|
|Target/Specificity||CDKN2D (AAH01822, 1 a.a. ~ 166 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||CDKN2D Antibody (monoclonal) (M08) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to form a stable complex with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. The abundance of the transcript of this gene was found to oscillate in a cell-cycle dependent manner with the lowest expression at mid G1 and a maximal expression during S phase. The negative regulation of the cell cycle involved in this protein was shown to participate in repressing neuronal proliferation, as well as spermatogenesis. Two alternatively spliced variants of this gene, which encode an identical protein, have been reported.
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Cunningham JM, et al. Br J Cancer, 2009 Oct 20. PMID 19738611.Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Zhang W, et al. Acta Biochim Biophys Sin (Shanghai), 2009 May. PMID 19430707.Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Goode EL, et al. Cancer Epidemiol Biomarkers Prev, 2009 Mar. PMID 19258477.Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. Agarwal SK, et al. J Clin Endocrinol Metab, 2009 May. PMID 19141585.Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Mavaddat N, et al. Cancer Epidemiol Biomarkers Prev, 2009 Jan. PMID 19124506.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.